August 20, 2022
Doyle's Guide

DibbsBarker boosts Brisbane IP practice

DibbsBarker has added to the firm’s Brisbane intellectual property and life sciences capabilities by appointing Former Hynes Legal Senior Associate to the role of Special Counsel with the firm’s Intellectual Property, Technology and Competition (IPT&C) team.

Sciascia’s legal credentials include acting for Bond University, Queensland Aboriginal and Islander Health Council, Plant Biosecurity CRC and Resiweb Limited on a variety of instructions including intellectual property and corporate & commercial.

Adding another string to her bow, Sciascia previously managed a genetic research centre, giving her unique insight into the life sciences market.

As the founding law firm for ResMed and having recently advised on the IPO of Regeneus, first biotechnology float on the ASX in three years, DibbsBarker is one of the leading law firms in the life sciences and healthcare markets. The firm is dedicated to the success of their life sciences clients and work hard to understand their unique situations and challenges as well as the dynamics of the sector as a whole.

Commenting on her appointment, Rachel said, “The DibbsBarker IPT&C team have a great reputation not only for being experts in the field, but for also being genuine people that you enjoy spending time with. It’s exciting to be part of a team which is ingrained in the life sciences industry and has in-depth knowledge of the research and development sector similar to my own”.

 

Share this page...
Follow by Email
Facebook
Twitter
LinkedIn
Share

Related posts

Leading Criminal Defence Lawyers – Queensland, 2022

Doyles Guide

Leading Criminal Law Barristers – Queensland, 2022

Doyles Guide

Leading Traffic & DUI Lawyers – Queensland, 2022

Doyles Guide

Criminal Law Rising Stars – Queensland, 2022

Doyles Guide

Leading Criminal Defence Law Firms – Queensland, 2022

Doyles Guide

Leading Administrative & Public Lawyers – Australia, 2022

Doyles Guide

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More